Targeting interferon I in SLE: a promising new perspective

被引：2
|
作者：
Rios-Garces, Roberto [1 ]
Cervera, Ricard [1 ]
机构：
[1] Hosp Clin Barcelona, Dept Autoimmune Dis, Barcelona 08036, Spain
来源：
LANCET RHEUMATOLOGY | 2020年 / 2卷 / 10期
关键词：
ANIFROLUMAB;
D O I：
10.1016/S2665-9913(20)30288-5
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E581 / E582
页数：2
相关论文
共 50 条
  • [1] TARGETING THE TYPE I INTERFERON SYSTEM IN SLE
    Ronnblom, L.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (04) : S84 - S84
  • [2] Ustekinumab: a promising new drug for SLE?
    Costedoat-Chalumeau, Nathalie
    Houssiau, Frederic A.
    LANCET, 2018, 392 (10155): : 1284 - 1286
  • [3] Targeting sphingosine-1-phosphate receptor modulator in SLE: a promising new therapeutic option
    Barilaro, Giuseppe
    Cervera, Ricard
    LANCET RHEUMATOLOGY, 2025, 7 (01): : e3 - e5
  • [4] Oxacyclododecindione - a new promising substance in SLE treatment
    Henke, Jenny
    Menke, Julia
    Erkel, Gerhard
    Kleinert, Hartmut
    Pautz, Andrea
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2014, 387 : S16 - S16
  • [5] A perspective on B-cell-targeting therapy for SLE
    Looney, R. John
    Anolik, Jennifer
    Sanz, Inaki
    MODERN RHEUMATOLOGY, 2010, 20 (01) : 1 - 10
  • [6] RETINOIDS AND INTERFERON - A NEW PROMISING COMBINATION
    BOLLAG, W
    BRITISH JOURNAL OF HAEMATOLOGY, 1991, 79 : 87 - 91
  • [7] Type I interferon correlates with serological and clinical manifestations of SLE
    Dall'Era, MC
    Cardarelli, PM
    Preston, BT
    Witte, A
    Davis, JC
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (12) : 1692 - 1697
  • [8] Dysregulation of type I interferon production and generation of autoantibodies in SLE
    Reeves, WH
    Kelly, KM
    Zhuang, H
    Sobel, E
    Scumpia, P
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 7 - 7
  • [9] Cause and consequences of the activated type I interferon system in SLE
    Maija-Leena Eloranta
    Lars Rönnblom
    Journal of Molecular Medicine, 2016, 94 : 1103 - 1110
  • [10] Who will respond to type I interferon receptor blockade in SLE?
    Aringer, Martin
    LANCET RHEUMATOLOGY, 2022, 4 (04): : E234 - E236
12345